QQQ   426.61 (-1.04%)
AAPL   168.24 (-0.67%)
MSFT   411.88 (-0.65%)
META   495.92 (-0.77%)
GOOGL   155.53 (+0.73%)
AMZN   181.24 (-1.13%)
TSLA   156.86 (-0.16%)
NVDA   847.34 (-3.07%)
AMD   155.39 (-4.94%)
NIO   3.93 (+3.15%)
BABA   68.99 (-0.89%)
T   16.14 (+0.31%)
F   12.05 (-0.33%)
MU   117.07 (-3.86%)
GE   155.49 (-0.81%)
CGC   6.45 (-3.73%)
DIS   113.09 (-0.69%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.28 (-0.24%)
XOM   118.38 (-0.26%)
QQQ   426.61 (-1.04%)
AAPL   168.24 (-0.67%)
MSFT   411.88 (-0.65%)
META   495.92 (-0.77%)
GOOGL   155.53 (+0.73%)
AMZN   181.24 (-1.13%)
TSLA   156.86 (-0.16%)
NVDA   847.34 (-3.07%)
AMD   155.39 (-4.94%)
NIO   3.93 (+3.15%)
BABA   68.99 (-0.89%)
T   16.14 (+0.31%)
F   12.05 (-0.33%)
MU   117.07 (-3.86%)
GE   155.49 (-0.81%)
CGC   6.45 (-3.73%)
DIS   113.09 (-0.69%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.28 (-0.24%)
XOM   118.38 (-0.26%)
QQQ   426.61 (-1.04%)
AAPL   168.24 (-0.67%)
MSFT   411.88 (-0.65%)
META   495.92 (-0.77%)
GOOGL   155.53 (+0.73%)
AMZN   181.24 (-1.13%)
TSLA   156.86 (-0.16%)
NVDA   847.34 (-3.07%)
AMD   155.39 (-4.94%)
NIO   3.93 (+3.15%)
BABA   68.99 (-0.89%)
T   16.14 (+0.31%)
F   12.05 (-0.33%)
MU   117.07 (-3.86%)
GE   155.49 (-0.81%)
CGC   6.45 (-3.73%)
DIS   113.09 (-0.69%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.28 (-0.24%)
XOM   118.38 (-0.26%)
QQQ   426.61 (-1.04%)
AAPL   168.24 (-0.67%)
MSFT   411.88 (-0.65%)
META   495.92 (-0.77%)
GOOGL   155.53 (+0.73%)
AMZN   181.24 (-1.13%)
TSLA   156.86 (-0.16%)
NVDA   847.34 (-3.07%)
AMD   155.39 (-4.94%)
NIO   3.93 (+3.15%)
BABA   68.99 (-0.89%)
T   16.14 (+0.31%)
F   12.05 (-0.33%)
MU   117.07 (-3.86%)
GE   155.49 (-0.81%)
CGC   6.45 (-3.73%)
DIS   113.09 (-0.69%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.28 (-0.24%)
XOM   118.38 (-0.26%)
NASDAQ:CRBU

Caribou Biosciences (CRBU) Stock Price, News & Analysis

$3.87
-0.14 (-3.49%)
(As of 03:16 PM ET)
Today's Range
$3.86
$4.09
50-Day Range
$4.01
$8.26
52-Week Range
$3.44
$8.59
Volume
1.44 million shs
Average Volume
1.64 million shs
Market Capitalization
$349.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.50

Caribou Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
468.2% Upside
$22.50 Price Target
Short Interest
Bearish
12.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of Caribou Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.76) to ($2.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.54 out of 5 stars

Medical Sector

690th out of 913 stocks

Biological Products, Except Diagnostic Industry

112th out of 147 stocks

CRBU stock logo

About Caribou Biosciences Stock (NASDAQ:CRBU)

Caribou Biosciences, Inc. is a cutting-edge biopharmaceutical company headquartered in Berkeley, California. Founded in 2011 by Dr. Rachel E. Haurwitz and other prominent scientists, the company is a leader in the field of genome-editing therapies. Caribou utilizes CRISPR-Cas technology to develop precision cell therapies for patients suffering from hematologic malignancies and solid tumors. The company's vision is to revolutionize the treatment landscape for devastating diseases by providing innovative and personalized therapies.

Caribou Biosciences' journey began as a spinoff from research conducted at the University of California, Berkeley, where Dr. Haurwitz and her colleagues worked on harnessing the CRISPR-Cas system for advanced gene-editing applications. Leveraging their expertise, the team established Caribou to explore the potential of genome editing in developing transformative therapeutics.

The company is committed to pushing the boundaries of science and medicine, focusing on creating precision cell therapies that target specific genetic mutations in patients' cells. By modifying these cells, Caribou aims to enhance antitumor activity and provide tailored treatments to address the unique genetic characteristics of each patient's disease.

Caribou Biosciences operates in the biological products industry, specializing in genome-editing therapies. The company's dedication to research and innovation has positioned it as a key player in the field, with significant potential to impact the future of medical treatments.

The company's mission statement revolves around the core belief in the power of genome-editing technology to unlock new possibilities for disease treatment and patient care. Caribou is committed to advancing its pipeline of precision cell therapies and translating cutting-edge science into transformative solutions for patients worldwide.

The leadership team at Caribou Biosciences comprises accomplished professionals with extensive expertise in the biopharmaceutical and scientific domains. Dr. Rachel E. Haurwitz, who co-founded the company and serves as the Chief Executive Officer, President, and Director. With a Ph.D. in Molecular and Cell Biology from UC Berkeley, Dr. Haurwitz was pivotal in developing CRISPR-based gene-editing technologies. Assisting Dr. Haurwitz is Ms. Ruhi A. Khan, the Chief Business Officer responsible for driving strategic partnerships and business development initiatives. Ms. Khan brings a wealth of experience in the biopharmaceutical industry and has been instrumental in shaping Caribou's collaborations. Dr. Syed Ali-aamir Rizvi serves as the Chief Medical Officer, contributing his expertise in clinical development and medical affairs. With a strong background in hematology and oncology, Dr. Rizvi is critical in guiding the clinical progress of Caribou's precision cell therapies. The management team's collective experience, dedication to innovation, and scientific prowess have propelled Caribou Biosciences to the forefront of the genome-editing industry.

Caribou Biosciences has demonstrated steady revenue growth over the past few years. However, the company is operating at a loss, with a net negative income of close to $100 million. The negative net profit margins result from substantial operating expenses associated with advancing the pipeline of precision cell therapies. Caribou Biosciences' innovative approach to precision cell therapies and its pioneering work in genome editing have garnered investor interest and positive sentiment, contributing to the stock's potential upside.

The stock performance of Caribou Biosciences is subject to various factors, including market conditions, investor sentiment, and news related to the company's progress. Investors closely monitor the company's milestones, clinical trial results, and partnership agreements, which can significantly impact the stock price.

Caribou Biosciences operates in the highly competitive field of biopharmaceuticals, focusing on genome-editing therapies. The broader industry has witnessed significant advancements in CRISPR technology, with various companies vying to develop precision cell therapies. Caribou's competitive advantage lies in its patented Cas12a chRDNA technology, which enables superior precision in genome editing and the development of armored cell therapies.

The company's pipeline of precision cell therapies presents promising growth opportunities. With its CAR-T and CAR-NK platforms targeting hematologic malignancies and solid tumors, Caribou aims to cater to patients with critical medical needs. The company's dedication to scientific excellence and pioneering research positions it well to capitalize on the potential of genome-editing therapies.

Caribou Biosciences faces several potential risks and challenges common to clinical-stage biopharmaceutical companies. These include uncertainties in clinical trials, regulatory approval processes, and market competition. However, Caribou's risk management strategies and scientific expertise serve as potential mitigating factors.

CRBU Stock Price History

CRBU Stock News Headlines

IRS Loophole Gives Americans An Escape From Inflation
In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.
CRBU Oct 2024 5.000 put
IRS Loophole Gives Americans An Escape From Inflation
In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.
Caribou Biosciences Shares Fall on Wall Street Miss
CRBU Oct 2024 2.500 call
CRBU Mar 2024 7.500 put
RBC Capital Keeps Their Buy Rating on Caribou Biosciences (CRBU)
See More Headlines
Receive CRBU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
4/17/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CRBU
Fax
N/A
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.50
High Stock Price Target
$30.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+461.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-102,070,000.00
Net Margins
-296.05%
Pretax Margin
-295.49%

Debt

Sales & Book Value

Annual Sales
$34.48 million
Book Value
$4.17 per share

Miscellaneous

Free Float
81,735,000
Market Cap
$362.18 million
Optionable
Optionable
Beta
2.47
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives


CRBU Stock Analysis - Frequently Asked Questions

Should I buy or sell Caribou Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Caribou Biosciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRBU shares.
View CRBU analyst ratings
or view top-rated stocks.

What is Caribou Biosciences' stock price target for 2024?

4 brokerages have issued 12-month price targets for Caribou Biosciences' shares. Their CRBU share price targets range from $13.00 to $30.00. On average, they predict the company's share price to reach $22.50 in the next year. This suggests a possible upside of 468.2% from the stock's current price.
View analysts price targets for CRBU
or view top-rated stocks among Wall Street analysts.

How have CRBU shares performed in 2024?

Caribou Biosciences' stock was trading at $5.73 at the beginning of 2024. Since then, CRBU stock has decreased by 30.9% and is now trading at $3.96.
View the best growth stocks for 2024 here
.

When is Caribou Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CRBU earnings forecast
.

How were Caribou Biosciences' earnings last quarter?

Caribou Biosciences, Inc. (NASDAQ:CRBU) announced its quarterly earnings data on Monday, March, 11th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.17. The business earned $3.56 million during the quarter, compared to analyst estimates of $5.17 million. Caribou Biosciences had a negative trailing twelve-month return on equity of 31.06% and a negative net margin of 296.05%.

When did Caribou Biosciences IPO?

Caribou Biosciences (CRBU) raised $202 million in an initial public offering on Friday, July 23rd 2021. The company issued 13,500,000 shares at $14.00-$16.00 per share.

Who are Caribou Biosciences' major shareholders?

Caribou Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Green Alpha Advisors LLC (0.09%). Insiders that own company stock include Barbara G Mcclung, Ryan Fischesser, Steven Kanner and Syed Ali-Aamir Rizvi.
View institutional ownership trends
.

How do I buy shares of Caribou Biosciences?

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRBU) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners